1. New Study Finds Vibration Testing More Reliable than Monofilament over Plantar Calluses

    Wynands et al’s recently published “Does plantar skin abrasion affect cutaneous mechanosensation?” brings into focus the importance of plantar callus debridement.  This study measured skin thickness, hardness, monofilament threshold and vibration perception threshold (VPT) in healthy participants over plantar calluses before and after “abrasion” (debridement). The intervention group was compared to a matched control group […]

  2. ETF128 selected for vibration testing in Benfotiamine clinical trials

    The company was please to learn that the ETF128 will be one of the vibration testing methods utilized in an international clinical trial assessing the effects of benfotiamine on patients with diabetic peripheral neuropathy (DPN). This randomized, double-blind, placebo-controlled study will compare  benfotiamine 300 mg twice per day to placebo over 12 months. Vibration testing with […]

  3. New ETF Study Demonstrates Enhanced Prediction of Diabetic Foot Ulcers

    The company is delighted to announce the publication of new original research utilizing the ETF. In this retrospective study, the ETF and Semmes Weinstein monofilament test (SWM) were evaluated for their accuracy in predicting ulcer occurrence in a community health center setting. Each test was assessed on its own and then combined to see which […]


      An excellent new monograph was just released from the American Diabetes Association on diabetic peripheral neuropathy (DPN). This document, authored by a panel of experts on the subject, updates providers on the latest guidance for the diagnosis and treatment of DPN.  Interestingly, a new appreciation for the impacts of the Social Determinants of Health […]

  5. New Review on Management of Diabetic Peripheral Neuropathy

    “Current concepts in the management of diabetic polyneuropathy” by Ziegler et al. was recently published in the Journal of Diabetes Investigation. The authors present an updated review of current therapeutic options for diabetic peripheral neuropathy (DPN). Care is taken to delineate those agents capable of altering the pathogenesis of DPN from palliative alternatives. Among the […]